





Schistosomiasis is a disease caused by a parasitic trematode worm that manifests primarily in the forms of intestinal and urogenital infections, and is transmitted by freshwater snails. The disease plagues more than 200 million people a year, primarily in poverty-stricken areas, and it is a major public health concern due to its large socioeconomic impact and widespread geographic distribution.  The disease consists of several stages including an initial rash, acute schistosomiasis, and chronic schistosomiasis. Children, women, fisherman, and farmers are at the highest risk for the disease. The disease is diagnosed primarily through the analysis of stool and urine samples. Treatment and preventative treatment consists of the consumption of praziquantel.  Primary control measures consist of the use of molluscicides and biocontrol, while prevention consists of mass drug administration, public health education campaigns, and wildlife management.  The best way to eliminate the disease is to develop a vaccine to disrupt transmission, but until then control and prevention should be the main focus to eliminate the disease. Combining molluscicidal water treatment and biocontrol techniques, combination therapy using artemether and praziquantel along with educational programs, and dual-utilization of wildlife management and agricultural modernization serve as the most effective ways of controlling the disease.
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In a perfect world, all infectious diseases on planet Earth should be able to be eradicated. Unfortunately, this is not realistic in the world today.  Three factors contribute to the theory of whether or not diseases can be eradicated. First, an intervention that can effectively interrupt the transmission of the disease should be made available.  Second, highly specific and sensitive diagnostic tools should be available to detect disease transmissibility. Third, humans are essential for the continuation of the life cycle of the pathogen, no vertebrae reservoirs exist, and the disease cannot amplify in the natural environment [1].  When it comes to this theory, schistosomiasis does not meet all three of the criteria for the potential for eradication.  In the case of schistosomiasis, the public health community should not focus on eradication; rather their primary objective should be to reduce and control the disease in the endemic areas.
Schistosomiasis is major public health concern due to its enormous health and socioeconomic burden in the world.  Schistosomiasis, otherwise known as bilharzia, is an acute and chronic crippling disease that is second only to malaria as the worst parasitic disease in the case of morbidity. Schistosomiasis is considered a neglected tropical disease that affects more than 200 million people each year in Africa, Asia, South America, and the Caribbean, while 700 million others are exposed to the disease [2].  Due to the chronic nature of the disease, closer to 440 million people a year are actively plagued by the disease due to its residual morbidity [3].  As of 2010, a mortality report showed that schistosomiasis resulted in more than 200,000 deaths per year [4].  The disease is caused by a parasitic trematode worm known as a schistoma that uses freshwater snails as the primary intermediate host for transmission to humans.  The three genera of snails that play the key role in the schistosome’s life cycle are Biomphalaria, Bulinus, on Oncomelania [5].  Although humans serve as a primary host for the disease, cats, dogs, ruminants, primates, and rodents serve as hosts for certain species of the parasite.  There are five major species of Schistoma that can infect humans: S. mansoni, S, japonicum, S. haematobium, S. intercalatum, and S. mekongi.  S. mansoni, S. japonicum, S. mekongi, and S. intercalatum manifest as an intestinal infection, while S. haematobium manifests as a urogenital infection [6].  The classical symptoms of intestinal schistosomiasis are characterized by abdominal pain, diarrhea, and blood in the stool, while the classical symptom of urogenital schistosomiasis consists of blood in the urine [7].  More advanced symptoms consist of liver and spleen enlargement and bladder cancer, fibrosis of the bladder and ureter, and infertility in intestinal and urogenital schistosomiasis, respectively [7].
Schistosomiasis, considered a disease of poverty, is an endemic disease in which 91.4% of cases occur in the poverty-stricken areas of Sub-Saharan African as of 2018 [2].  People become infected by both occupational and recreational activities that result in the contact of water that is infested with freshwater snails that serve as a reservoir for the parasitic worm.  Lack of hygiene, proper sanitation, and potable water contribute to the transmission of the disease [6].  The groups that are at the greatest risk for transmission are school-aged children, fisherman, rice farmers, and women that are in frequent contact with fresh water bodies in poor communities [6].  
The use of mass and periodic distribution of the medication, praziquantel, serves as the major control technique, but this is not always financially feasible in extremely poor communities. Not only is introduction of mass dispensing not economically feasible, but it also does not protect against any future infections. As with all antibiotics, mass dispensing of praziquantel may result in the development of resistant trematode worms [8].  There are several methods in which the public health community can focus on the control and reduction of the disease in endemic areas. Educational programs, development of vaccines, snail control, and improved sanitation serve as more comprehensive and feasible programs that can aid in the reduction and control of the disease.  Past successes and control mechanisms used in areas such as China can potentially be implemented in poor and endemic areas to aid in the fight against this disease.  The key to the eradication of any disease is to create a vaccine, and looking into the genomics of the schistosome to identify potential targets could lead to a vaccine [8].  The primary objective of this essay is to identify global burden, life cycle, pathogenesis, morbidity/mortality, diagnosis, treatment, and previous prevention and control techniques, and new, feasible, and economically sound techniques to reduce the disease in the communities that are most affected.
1.1	DISEASE BURDEN
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Schistosomiasis comes in two forms. The two types affect different parts of the human body. There is urogenital schistosomiasis and intestinal schistosomiasis [2]. Both are debilitating, and both are found throughout multiple places in the world. Due to its morbidity and widespread geographic distribution, it is a major public health issue that needs to be at the forefront of importance.  The geographic range of schistosomiasis is also associated with the distribution of the snail intermediate hosts.  Areas that are endemic for the disease are able to support large populations of snails that host these parasites are identified in order to determine geographic distribution as well.  Species like S. mansoni and S. haematobium are able infect snail species of the aquatic genus, Biomphalaria and Bulinus, while S. japonicum are able to infect the amphibious snail genus, Oncomelania [9].
Schistosomiasis is a disease that primarily infects poor, rural communities with poor sanitation, and where the primary source of income comes from agricultural and fishing careers. When looking at geographic distribution, the five species of schistomes are found in widespread locations. Urogenital schistosomiasis, which is caused by S. haematobium, is found in Africa, the Middle East, and even areas of France [2][6].  S. haematobium is found in southern and Sub-Saharan Africa in freshwater lakes and rivers [2][6]. There are also recorded cases of transmission in the Nile River Valley in Egypt and the Maghreb region of North Africa. Intestinal Schistosomiasis, which is caused by S. mansoni, S. mekongi, S. intercalatum, and S. japonicum, is found in a much wider spread area [2][6].  S. mansoni is found in southern and Sub-Saharan Africa in freshwater, as well as the Nile River Valley of Sudan and Egypt [2][6].  S. mansoni can also be found in several areas of the Caribbean (St. Lucia, Martinique, Dominican Republic, and Guadeloupe), Venezuela, Suriname, and Brazil [2][6]. S. mekongi is found in areas of Cambodia and Laos. S. japonicum is found in China, Indonesia, and the Philippines [2][6].   Lastly, S. intercalatum is found in Central and West Africa, primarily in the Rain Forest areas of West Africa [2][6].
A total of 74 countries are affected by schistosomiasis [8]. African countries have the highest prevalence, and have the largest number of people that are seen to be at the highest risk for the disease [8][10]. While 42 countries in Africa are considered to be endemic for the disease, the areas in the Eastern Mediterranean have at least 16 countries that are also considered to be endemic for the disease [8].  Although the disease is not found anywhere in North America, it is endemic in at least 10 countries in the Americas [8][10].  Due to the current state of globalization, it is becoming more and more possible that the disease can be brought to the United States due to traveling to areas that are considered to be endemic [2].








When looking into the life cycle of this parasitic infection, it is important to note that disease transmission can be decreased and increased due to natural effects such as environmental changes and the natural introduction of fluctuating predator-prey relationships.  That is why looking deeper into the life cycle of the disease will likely be one of the keys to potential eradication.  The life cycle of schistosomiasis involving a human host is common for both urogenital and intestinal schistosomiasis.  First, eggs are excreted by a human host in the feces or urine of an individual into freshwater sources. Following the excretion, the eggs hatch miracidia, which are capable of swimming to a snail, which serve as an intermediate host.  Once the snail is infected, successive generations of sporocysts begin to persist within the snail, while free-swimming cercariae are released.  The cercariae penetrate a human host when they come into contact, and they lose their forked-tail to become schistosomulae and begin circulating throughout the infected host. The schistosomulae then migrate to the portal blood in the liver and mature into adult schistosomes.  The next step is slightly different for the two types of schistosomiasis.  During intestinal schistosomiasis, (S. mansoni, S mekongi, S. japonicum, and S. intercalatum) adult paired worms migrate to the mesenteric venules of the bowel/rectum.  During urogenital schistosomiasis, S. haematobium adult paired worms migrate to the venous plexus of the bladder, and the rectal venules in some cases.  The adult worms lay eggs that circulate into the liver and are excreted in the feces in the case of intestinal schistosomiasis. The adult worms lay eggs that circulate into the bladder and urethra in the case of urogenital schistosomiasis.  S. haematobium is primarily excreted in the urine, but can be found in the stool. S. mansoni, S. mekongi, S. intercalatum, and S. japonicum are excreted in the feces, but in some cases S. japonicum is excreted in the urine as well as the stool.  When the life cycle of the disease reaches this point, eggs found in the urine and stool samples of the individuals are the primary way to diagnose the those with the disease [13]. 
1.3	PATHOGENESIS AND MORBIDITY
Contrary to popular belief, it is known that the infection of the snail itself is not actually responsible for the morbidity of the disease, but rather the eggs that are excreted create the issues associated with both acute and chronic schistosomiasis.  The eggs that are released become lodged within the intestines and liver in intestinal schistosomiasis, while the eggs resulting from the S. haematobium infection become lodged in the bladder and urethra. The release of the eggs into human tissue results in activation of a host immune response that leads to the formation of granulomas and the persistent development of inflammation that is picturesque of the common symptoms associated with the disease [14].  In children, schistosomiasis has been seen to be a risk factor for mental retardation and even growth stunting [15].
There are several stages of schistosomiasis. Schistosomiasis can consist of dermatitis, acute schistosomiasis, and chronic schistosomiasis.  The initial stage, dermatitis is caused by the penetration of the skin by the cercariae and is most often seen in those infected with the disease for the first time [16].  The dermatitis is characterized by a papular rash that typically occurs within the first few hours or days of the infection [16].  Swimmer’s itch, a much more severe form of dermatitis, may occur in cases where the primary host of the schistosome is a mammal or bird [16]. In these cases, once the cercariae infiltrates the skin, it burrows and elicits and allergic response [16].  The dermatitis stage is often not seen in people that live in endemic areas due to inherited immunity from mothers who were previously infected with helminthic parasites [16].
Acute schistosomiasis occurs after the occurrence of dermatitis, and it primarily occurs in individuals that lack immunity due to initial exposure to the disease [16]. Symptoms of acute schistosomiasis usually occur during the first few weeks to months after acquiring the infection [16]. It is most often categorized by a syndrome known as Katayama fever [16]. The characteristic traits of Katayama fever show up typically four to six weeks after the infection and can last for up to 10 weeks [16].  Katayama fever is most likely caused by the maturation of the parasitic worm as it passes through the liver and lungs and as the eggs excreted by the mature schistosome begin to elicit an inflammatory response [16].  Katayama fever is characterized by symptoms such as fever, lethargy, urticarial rash, liver and spleen enlargement, and bronchospasms [17]. Like the dermatitis stage, the stage is typically not seen in those who call endemic areas home except for infections caused by S. japonicum [16]. Those infected by this particular species can develop Katayama Syndrome during any infection [16].  In most cases, the symptoms of the syndrome go away, but in some cases, diarrhea, weight loss, abdominal pain, and rash persist for months to years [4].  
Chronic schistosomiasis is the stage of the disease that tends to be the most debilitating aspect due to its persistent and crippling nature.  As the disease persists, the body begins to downregulate the inflammatory response to the eggs as a form of immunological tolerance [16].  At the site of the initial granulomas, collagen deposits will replace the lesion [16].  The primary clinical manifestation of the disease is associated with these granulomas and fibrotic lesions that form due to a large amount of disturbances that interrupt the critical stages of the downregulation of the immunological response, but severity is associated with the location of the Schistosome eggs and the overall intensity of the infection [16].
There are several complications that can arise from the chronic stage of the disease. For example, gastrointestinal disease results due to eggs being retained in the gut wall causing chronic inflammation, hyperplasia, ulceration, micro-abscess formation, and polyposis [16].  In very severe cases, the gastrointestinal disease may present as colonic or rectal stenosis [16]. Liver disease is another potential complication. Eggs that embolize in the liver promote the formation of fibrosis in severe infections [16].  Hepatomegaly may be a result due to the formation of the granulomas [16].  Genitourinary complications can lead to issues such as bladder calcification, ureteric obstruction, renal colic, hydronephrosis, and even renal failure [14]. Chronic schistosomiasis has also been linked to several cases of bladder cancer in endemic countries [14].  Urinary schistosomiasis may also result in sterility, premature labor, and spontaneous abortions [14].
A much less common, but extremely severe form of the disease may result in neuroschistosomiasis.  In cases of neuroschistosomiasis, adult worms that typically migrate to the urinary tract or intestinal tract, instead migrate to the brain and spinal cord and infect the central nervous system (CNS) [18]. Thousands of eggs are released in the CNS, which results in the formation of granulomas and then fibrotic lesions after the inflammatory response is downregulated that result in severe symptoms [18].  Symptoms of neuroschistosomiasis consist of encephalopathy, transverse myelitis, nystagmus, speech disturbances, motor weakness, lumbar and lower limb pain, sensory loss, and bladder dysfunction [18].  Although this is seen as an extremely severe case, it can still be treated by praziquantel [19].
1.4	DIAGNOSIS
Intestinal and urinary schistosomiasis are diagnosed in very similar ways.  Diagnosis of intestinal schistosomiasis is made by observing eggs within a smear of a stool sample. In the case of urinary schistosomiasis, eggs are observed via microscopy in urine samples [20].  Multiple tests may be required because the rate at which the eggs shed varies over time in both types.  In a situation where several clinical symptoms appear, but no eggs are detected in the stool or urine, other testing may be required; for example, a bladder or rectal mucosa biopsy.  PCR testing can be done in order to determine if the DNA of the Schistosoma species is present.  Biochemical markers detected in serological tests may also reveal the presence of the disease.  Serological testing can also be used in order to detect whether or not certain antibodies are circulating in the bloodstream [6][14] Indirect methods of diagnosis include ultrasound, liver biopsy, and histological examination [14]
1.5	TREATMENT
The antihelminthic drug known as praziquantel is the primary oral medication used to treat schistosomiasis. Praziquantel serves as a treatment by killing the adult worms [21].  Praziquantel is effective with one hour of ingestion, and is safe and effective in all people including children and pregnant women [21].  In the case of S. mekongi and S. japonicum are dosage of 40 mg/kg orally split within a 24 hour period is optimal in order to treat the disease [21].  In the case of S. mansoni, S. intercalatum, and S. haematobium, a dosage of 60 mg/kg orally split within a 24 hour is optimal to treat the disease [21].  In the case of preventative treatment a single dose of 40 mg/kg taken orally is found to be extremely effective [21]. Studies have been done to determine whether or not 60 mg/kg would be more effective in the treatment [22]. Although, it is seen to have a similar cure rate, 60 mg/kg is associated with an increased amount of adverse side effects [22].   A primary issue with praziquantel is that certain species of schistosomiasis are starting to develop a resistance to the treatment [23].  In certain cases where S. haematobium and S. mansoni are considered to be endemic, mass treatment has resulted in some of the praziquantel treatment being deemed unresponsive [23]. In these cases, continuous treatment for three to six weeks has been determined to be effective in killing the parasitic worms [23].
A few other antiparasitic drugs are also being developed in order to treat the disease. Praziquantel is not effective during the first 3-21 days of the immature worm infection [24]. In these cases, the disease is treated using the antimalarial drug known as artemether because it has been determined to be effective in killing immature schistosomula [24].  Combination treatments of artemether and praziquantel have been found to be more effective than monotherapy in clinical trials [24].  Oxaminique is used to treat S. mansoni infections as well [25].  
2.0 	SPECIFIC AIMS
This literature review focuses on two main aims. The first being to identify a current perspective on the global burden, the life cycle, the pathogenesis and morbidity, the diagnosis, and the treatment of schistosomiasis. The second being to identify and analyze the past and present control and prevention programs around the world in order to identify the best methods to reduce and control the global burden of schistosomiasis. 
3.0 	METHODS
A literature review was performed utilizing PubMed and Google Scholar that focused on schistosomiasis control and prevention procedures both past and present. Over 700 articles were identified, but only 50 articles published between 1961 and 2018 were used in the literature review. 
3.1	INCLUSION CRITERIA
Studies from 1961 to 2018 were included in order to gain an understanding of all the different control and prevention techniques that have taken place.  Only studies that looked at endemic areas were included in the literature review.  Search terms included: Schistosomiasis AND Control (518 results), Schistosomiasis AND Prevention (137 results), Schistosomiasis AND Biocontrol (2 results), Schistosomiasis AND Mass Drug Administration (57 results).
3.2	EXCLUSION CRITERIA
Studies that did not focus on endemic areas were not included in the review. Cost analyses and meta-analyses were not included in the study. Studies that provided primary commentary on control and prevention programs were not included in the literature review. Studies that were not published in English were not included in the study. 
4.0 	PREVENTION
There are several steps in which individuals can take in order to prevent the transmission of schistosomiasis. The Centers for Disease Control and Prevention state that avoiding swimming untreated freshwater where the snail intermediate hosts may inhabit [6].  Public awareness is also another very powerful tool that can be used in the fight against schistosomiasis.  Eliminate direct contact by drinking only clean water, filtered water, or bringing the water to a boil before using it to bathe, do laundry, or ingest [6].  Another potential way to avoid infection is to utilize proper, vigorous towel drying techniques to dislodge any cercariae attempting to penetrate the skin directly after exiting the freshwater. In those that have no choice but to be exposed to the water, a topical insecticide can be used in order to serve as minimal protection from the cercariae [6].
4.1	MOLLUSCICIDES
Prevention can take on many forms. For example, eliminating the snail host serves as a way to eliminate transmission. If the snails are not present in the water to continue the life cycle, there will be a decrease in prevalence.  There have been several snail control programs implemented that utilize molluscicides as a control mechanism [8]. Molluscicides utilize both chemical and natural treatments to kill the snail hosts of the disease and also have a biocidal effect on the snail larvae [8].  
Egypt utilized copper sulfate as a molluscicide in 1940, followed by sodium pentachlorophenate in the 50s [26].  Nearly 20 years later the WHO listed several other compounds as potential molluscicides, but only niclosamide is recommended for use [8].  Current niclosamide control campaigns have been met with several successes.  In China, niclosamide treatments resulted in over a 90% mortality rate among snails [27].  These rates show that the molluscicidal control efforts were successful, but more than one treatment is needed to completely reach all the snails, and yearly treatment would be required in order to eliminate future invading snails [27].  Not only is niclosamide effective, it shows no toxicity to humans [28].  One issue that comes along with the use of the chemical compounds is not only limited cost-effectiveness of multiple treatments, but also the toxicity to other organisms in freshwater that can disrupt the current ecosystem [29].  
Natural molluscicides are a more cost-effective protocol that have been looked into as a way to control the intermediate host snail population.  A plant extract known as Aridan and aridanin resulted in a decreased release of cercariae and also showed potential mortality related activity in the infective cercariae released by the snail [30]. A butanol extract from endod berries was also seen to have molluscicidal activity in a potential snail host, but the issue with endod is that it also extremely toxic to freshwater fish and amphibians [31].  A methanol extract of Jatropha curcas showed a toxic effect on mollusks and schistosome eggs in low doses [32]. Flooding out the snails and using ditches to trap them is another way to control snail populations in endemic areas [33].
4.2	BIOLOGICAL CONTROL
Another interesting method that is being looked into as a way to eliminate disease is through the biological control of snail hosts through the introduction of a predator-prey relationship.  Snails of the genus Thiara have been seen to serve as competitors against Biomphalaria spp., which are prominent intermediate hosts [34].  In a study in the Caribbean, three years after the introduction of Thiara, the Biomphalaria spp. were completely eliminated from the sites in Martinique and St. Lucia [34].  Thiara spp. snails are not as effective in the elimination in deep waters with a large amount of vegetation, but are extremely effective in shallow, oxygenated waters [34].  Not only have these snails eliminated the potential hosts, but they have maintained colonization to prevent potential colonization by the snail intermediate hosts at potential transmission sites [34].  
In Puerto Rico, Marisa cornuarietis snails were introduced to reduce that rate of the snail intermediate host [35].  After 21 years of constant reintroduction, B. grabaltar were eliminated in 70% of the reservoirs due to colonization [35].  The results also showed that this control technique was inexpensive, and could be initiated in endemic areas due to cost-effectiveness [35].  Predatory freshwater prawns have also been analyzed as a way to control the snail intermediate hosts [36].  Two species of Macrobrachium were shown to predate on the snails, hatchlings, and eggs of snail intermediate hosts, and they are also able to consume over 10% of their body weight [36]. In the Senegal River Basin, the reintroduction of these prawns resulted in an 80% decrease of infected snails, 18% reduction in schistosome presence, and an overall egg rate reduction [36]. Procamburus clarkii, a North American crayfish, predate on the eggs of Biomphalaria spp. of snails and are able to exponentially decrease the rates of snail populations in freshwater sources [37]. In a small study, the African catfish served as a natural predator of the snails when having a limited food supply [38].  
5.0 	CONTROL
The Centers for Disease Control and Prevention cite two main ways of eliminating schistosomiasis. The first involved reducing transmission of the disease itself, while the other consists of eliminating the snail intermediate hosts [6].  A well-developed sanitation system is always going to be the best option when it comes to decreasing the transmission of the disease, but this isn’t always possible in poor, endemic countries [6].  Mass distribution of praziquantel is a measure that has been taken in order to control transmission [6]. Specific targets of these campaigns are at risk groups such as school-age children [6].  Certain chemicals such as molluscicides can be used in order to eliminate the snail host in endemic areas, but they run the risk of introducing a chemical that could harm other wildlife within the freshwater [6]. Also, the freshwater needs to be constantly monitored, and the levels need to be maintained in order to stop invading snails [6]. Biocontrol techniques that utilize the introduction of predator-prey relationships can also be used a form of snail control [6].  Control may also involve management of wildlife that can serve as intermediate hosts for the disease [6]. 
5.1	MASS DRUG ADMINISTRATION
One of the very first control efforts in the fight against schistosomiasis occurred in Egypt through the use of mass drug administration (MDA) in the 1920s [26]. Mass drug administration is the administration of mass amounts of medicines to an entire at-risk population [8]. Moving forward all the way to 2018, MDA is still looked at as the best way to control schistosomiasis [6].  The WHO currently states that the coverage rate for preventative chemotherapy should be about 75% for at-risk school-age children [2].  In a recent study performed in the Philippines in 2015, the WHO determined that the coverage rate was at only 43.5% [39]  The reason for the low rate was due to the lack of education about praziquantel and schistosomiasis itself [39]. People feared the adverse effects of praziquantel and did not understand the actual process of the drug’s administration [39].  In a systematic review conducted by Burnim et al., it was seen that the coverage rates could be increased by an educational program that was both school and community-based in order to reach a much larger population base [40]. A study conducted by Sinuon et al., in Cambodia looked at baseline prevalence rates of schistosomiasis before and after the mass distribution of praziquantel at the treatment dosage 40 mg/kg [41].  Coverage rates went as high as 86% during the course of the eight year program beginning in 1994 [41].  In 2004 no cases were reported and only three were reported in 2005, and there continues to be lack of severe morbidity in any cases [41].  In a study that looked in MDA in Tanzania, it was determined that the prevalence of urinary schistosomiasis was over 9 times less than those were not given the praziquantel treatment among school-age children [42].  Overall prevalence among the community dropped from 26% to 15% over the course of a year [42].  
In 1992, China began a mass chemotherapy campaign to aid in the control and prevention of schistosomiasis in endemic areas in Asia [43].  In a marshland region, prevalence was reduced from 25.12% to 13.15% during a 3 year MDA campaign using the WHO recommended dosage of 40 mg/kg [43].  After 5 years, prevalence was reduced from 16.7% to 4.4% in Sihu Lake [43]. In Pyong Lake, prevalence decreased from 15.6% to 2% during a 3 year campaign [44]. The cases also saw a decrease in severity based upon egg reduction in stool samples and hepatic fibrosis [44].  A study conducted in Sierra Leone showed that an MDA campaign could decrease prevalence as well. The study showed that an initial MDA campaign decreased the prevalence of schistosomiasis by 30.8%, and it lowered the prevalence among school-age children by 25.7% which are at the greatest risk for the disease [45][46].  Following a three year campaign, MDA resulted in a 67.2% reduction [45][46]. Along with a study in endemic regions of China, the severity was decreased by nearly 90% based upon severe morbidity and egg shedding reduction [45] [46].  
The issue then becomes that 260 million are in need of treatment, yet praziquantel treatment only reaches about 15% of those in need [2].  The WHO cites that a 75% coverage rate is required to be effective in reducing the rates of schistosomiasis [2]. In 2010, it was shown that over 100 million school-aged children required treatment, yet only 19% of them were actually receiving treatment [2].   In 2000, a mass drug administration campaign was initiated in highly endemic communities of the Philippines.  A treatment site was targeted on a community basis, but there was a very low participation rate.  The overall participation rate was slightly above 50%, and those that actually took the medication were at a rate of less than 50% [47].  When a cross-sectional analysis was performed in the Philippines in 2015, several factors were associated with the 43.5% coverage rate that had been assessed earlier [39].  Females, individuals 18-30, those that lacked knowledge about schistosomiasis, and those were previously noncompliant were significantly associated with a lack of compliance [39].  This shows that the gap in noncompliance is largely associated with a lack of awareness about schistosomiasis. 
From these studies, one can see that mass drug administration campaigns of praziquantel  are viable options for the control and prevention of schistosomiasis. The question then becomes why are these programs not feasible in the elimination of schistosomiasis alone.  The results tend to show that the coverage rates are lacking due to several reasons. Also, uptake is relatively low.  These low rates are the results of a lack of education, a lack of awareness, and perceived side effects [47].  Side effects are often minor, but they include things like diarrhea and abdominal cramping that lead to a lack of compliance [48].  Those that had knowledge of schistosomiasis were 1.85 times more likely to take the medication, and those that received education from health professionals were more than 5 times more likely to comply with the treatment [49].  Also, these mass drug administration campaigns tend to be targeted towards school-age children, but older at-risk adults and pre-school age children need to be focuses as well. In a matter of cost-effectiveness, a community-wide based approach is more effective [49]. The community-wide based administrations reach much larger groups outside of school-age children, due to the fact that several school-age children that are at high-risk are not actually enrolled in schools [40].  Another issue is that those that are untreated tend to lack any connection with proper sanitation which makes them an at-risk group [40].  The bitter taste of praziquantel itself is also an issue when it comes to compliance, along with the time of administration [50].  Several community members are unable to attend all campaign administration sessions due to their nomadic jobs. Cattle breeders who are considered to be a high-risk group for the disease serve as nomads which means they are not a focus of the community-wide approaches [40].  
5.2	EDUCATION PROGRAMS
The studies that looked into mass drug administration show that public health education is very important when it comes to the control of the transmission of the disease.  In a study in Ghana, education about schistosomiasis was inadequate [51]. Most people thought that having schistosomiasis was a sign of “manhood” and that the red color of the urine was a result of sugar cane consumption [51].  After these community members were educated they began to experience an expansion of knowledge that led them to develop latrines in an attempt to increase sanitation [51].  Health educators provided them with a way to avoid utilizing untreated freshwater for defecation and urination [51].  In China, promoting the use of fecal containers greatly reduced transmission rates during educational campaigns [52].  After three years of an education program in boatman and fisherman, knowledge about schistosomiasis increased by nearly 70%, increased the use of the fecal containers by over 50%, and increased the use of public toilets by more than 80%.  This also led to a nearly 10% decrease in prevalence of S. japonicum in China [52]. Education is very vital in the fight to eliminate schistosomiasis along with mass drug administration.
5.3	WILDLIFE MANAGEMENT
Wildlife management is another important tool that may be able to be utilized in order to fight schistosomiasis.  A disease known as guinea worm is a disease that is near to being eradicated.  Like the guinea worm, schistosomiasis also has several intermediate hosts that can aid in the transmission of the disease [53]. A campaign to tether animals such as dogs is currently very successful in helping the eradication of the disease [53].  Ruminants, dogs, cats, mice, and birds serve as intermediate hosts in the case of schistosomiasis.  A campaign to tether dogs and cats, and deter mice and birds can be used as an effective measure to decrease the prevalence of schistosomiasis in endemic countries.  When it comes to cattle, it may be appropriate to find ways to eliminate their direct contact with freshwater, and provide ways to dispose of their defecation in order to better manage the wildlife aspect of the disease.  
Several successes in the elimination of S. japonicum in China utilize a form of wildlife management. Bovids are intermediate hosts of S. japonicum, and their defecation results in runoff in the grasslands that drain into freshwater sources. These bovids are used in an effort to aid with farming techniques. In order to eliminate the use of these hosts in China, a program was created to provide the farmers with mechanical equipment to use for their farming.  Along with use of fecal containers, tap water, and latrines, this program was able to decrease the rate of S. japonicum infection to less than 1% in endemic villages [52].
5.4	VACCINE POTENTIAL
The only true way to eliminate schistosomiasis is through the development of a vaccine [1].  The initial vaccine trials done in the 90’s were not very successful (less than a 40% efficacy rate) [54].  New approaches are being taken to identify a novel vaccine.  Bilhvax, a schistosome glutathione S-transferase candidate is a target for urinary schistosomiasis [54]. The vaccine has shown effectiveness in reducing transmission and also decreases the rates of egg shedding [54].  This vaccine has the potential to decrease transmission, and reduce the morbidities associated with mature infections [54].  Intestinal schistosomiasis is also currently being evaluated to determine a potential vaccination.  The potential targets of the vaccine are an integral surface membrane protein and a fatty acid binding protein expressed in those with S. mansoni infections [55].  If these vaccines produce successful results, they could be a key player in the elimination of schistosomiasis.  Potential for these vaccines to be used in ruminants will also decrease the potential transmission via other intermediate hosts [55]  
6.0 	DISCUSSION
Schistosomiasis continues to be a disease that plagues humans on a global scale. The disease persists and continues to adversely affect the areas in which it is endemic. Although several steps have been taken to combat this terrible disease, this disease is still endemic in several countries. Despite large-scale mass drug administration campaigns and widespread snail control programs, this disease continues to thrive in developing nations such as sub-Saharan Africa.  In order to develop the best methods to lead to the elimination of the disease, researchers need to look into the successful efforts and determine the best approaches for the endemic areas that still exist today.
No single program alone can be successful in the fight against schistosomiasis, but when they are used in conjunction there is a chance to eliminate this disease.  Molluscicidal distribution campaigns can work very well when they are utilized on a yearly basis, but they cannot elicit a 100% mortality rate among the snails.  When used in conjunction with certain biocontrol techniques such as the introduction of Thiara spp. snails, the newly introduced predators will eliminate what is left over from the initial molluscicidal treatment and continue to colonize long after the intermediate hosts are removed from the ecosystem to prevent re-colonization.  In deeper waters that are poorly oxygenated and snail predator cannot thrive, introduction of prawns and fish that consume the snail intermediate hosts could serve as a means of total elimination because these predators do not serve as potential hosts to the worm.
Mass drug administration plays a key role in the treatment and prevention of the disease, but a MDA campaign cannot be completely successful on its own.  The fact that some campaigns only target school-age children, and do not always provide a proper educational campaign lead to poor coverage rates [39]. These campaigns should be community-based and focus on all the risk groups. These campaigns should be flexible enough to meet the needs of all those that are at risk. When mass drug administration is utilized, it must be used in conjunction with a public health education campaign because praziquantel itself cannot protect people from recurring infections.  The public must be led to understand what schistosomiasis is, how it is transmitted, and what it takes to combat the transmission from proper drying techniques, to the proper disposal of human waste, to the consumption of praziquantel.  Praziquantel campaigns could also include the use of artemisinin-derivatives because when used as a combination therapy, these drugs can fight both the immature and adult worms that generate this debilitating disease. In order to decrease the chances of resistance to praziquantel, oxamniquine should be used in areas where infections are due primarily to S. mansoni. Through these campaigns, the communities should be provided with improved access to proper sanitation and clean water whether it be through the development of latrines and water-boiling education.  
Wildlife management and agricultural modernization may also play a very important role in the elimination of this horrible disease.  From China’s success, one can see that this disease can continue to wreak havoc due to the infection of certain intermediate hosts like cattle. If farmers in endemic areas can be provided with proper machinery as opposed to the use of potential reservoirs to perform their work, the disease will continue to dissipate in endemic communities due to a lack of environmental contamination from the ruminants. In the cases where dogs and cats serve as hosts, utilizing the guinea worm methods of control such as tethering can be implemented by limiting their contact with freshwater sources. Also, proper steps could be taken to ensure the proper disposal of their waste.  If fisherman are provided with the proper tools to carry out their day-to-day activities, direct contact with freshwater sources will be limited, their risk for disease will decrease, and overall prevalence will continue to be reduced.
There is a light at the end of the tunnel when it comes to schistosomiasis, but it is important to understand that it will take a global effort to combat the disease.  Until there is a vaccine that serves as means to reduce transmission, public health must put combination control and prevention efforts at the forefront of this battle.  Public health professionals need to continue to look at past successes and failures in all cases of disease elimination and eradication to guide them in program development, while also engaging the stakeholders.
7.0 	LIMITATIONS
There are quite a few limitations when looking at these studies. In studies that include mass drug administration, attrition bias needs to be accounted for because there will be participant losses due to the potential adverse side effects to the medication.  Also, in poverty-stricken areas, there will be some sort of loss to follow-up bias due to dropouts and absenteeism. The studies on drug administration may also be affected by potential non-adherence.  In the case of some of snail control mechanisms, such as the African catfish may have a lack of generalizability affecting the external validity. Although it may seem efficacious, it may be lacking in efficiency due to the small sample size. Small sample size also allows for a higher rate of random error. When doing the literature review, notice was taken that the primary articles that were published were articles that showed positive or effective results. There was not a lot of literature on the failures of the schistosomiasis control campaigns.  Therefore, there seems to be some sort of publications bias. Selection bias may have potentially played a role due to the fact that only studies published in English were used in this literature review.
8.0 	FUTURE DIRECTIONS
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